Integer Holdings Co. (NYSE:ITGR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $148.56.
A number of brokerages have recently issued reports on ITGR. Truist Financial lifted their price target on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Citigroup boosted their target price on shares of Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, December 11th. Raymond James started coverage on shares of Integer in a research report on Friday, March 28th. They set an “outperform” rating and a $145.00 price target for the company. KeyCorp lifted their price objective on shares of Integer from $144.00 to $154.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Benchmark boosted their price objective on shares of Integer from $140.00 to $150.00 and gave the stock a “buy” rating in a research note on Friday, February 21st.
Read Our Latest Analysis on Integer
Institutional Inflows and Outflows
Integer Stock Performance
Shares of Integer stock opened at $106.39 on Friday. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The stock’s fifty day moving average price is $125.89 and its 200-day moving average price is $131.28. The firm has a market cap of $3.58 billion, a P/E ratio of 31.66, a P/E/G ratio of 1.72 and a beta of 1.09. Integer has a 12 month low of $104.93 and a 12 month high of $146.36.
Integer (NYSE:ITGR – Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a return on equity of 11.65% and a net margin of 6.92%. The business had revenue of $449.50 million during the quarter, compared to analysts’ expectations of $446.28 million. On average, equities research analysts expect that Integer will post 6.01 earnings per share for the current fiscal year.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
Read More
- Five stocks we like better than Integer
- What is a SEC Filing?
- Tariff-Proof Stocks: 3 Big Bargains With Huge Upside Potential
- How to start investing in penny stocks
- Qualcomm Breaks Down But RSI Signals It’s Severely Oversold
- What is the S&P/TSX Index?
- Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.